Deleted Tweet from Scott Gottlieb, R-D.C.
Deleted Tweet from Scott Gottlieb, M.D.
SteveFDA (R-D.C.)
@SGottliebFDA
Politwoops no longer follows this account.
Because of the slow progression and time required to do trials to evaluate clinical endpoints such as survival, the FDA is outlining a path for considering improvements in liver histology as endpoints reasonably likely to predict clinical benefit to support accelerated approval.
It looks like this tweet was replaced by the next tweet from @SGottliebFDA.